Business Context and Reporting Period
This Form 8-K Current Report was filed by Novanta Inc. on December 1, 2025. The filing serves as a Regulation FD disclosure regarding a material change in the company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
Effective December 1, 2025, Novanta Inc. appointed Alexander Manganiello to the roles of General Counsel and Corporate Secretary. In this capacity, Mr. Manganiello will lead the company's global legal, regulatory, corporate secretary, and trade compliance organizations.
Management Commentary and Background
- Experience: Mr. Manganiello brings 30 years of experience with global public companies across multiple industries.
- Previous Roles:
- Vertex Pharmaceuticals Incorporated (2019–2025): Vice President, Deputy General Counsel.
- Pfizer Inc. (2004–2019): Held various increasingly senior legal roles.
- Ropes & Gray: Practiced law within the corporate department prior to joining Pfizer.
- Education: Holds an A.B. in Biology from Harvard University and a J.D. from Suffolk Law School.
Investor Verification Checklist
- Confirm the effective date of Alexander Manganiello's appointment (December 1, 2025).
- Verify the specific scope of his responsibilities (legal, regulatory, corporate secretary, trade compliance).
- Review the company's subsequent filings for any impact on legal strategy or compliance frameworks resulting from this leadership change.